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, ‘llte abn of this study wns to assess whether hyper- 
slon eontributes to the e 
intn er suppression 
Iear nsibte for cnr- 
The pertluorocbemtcal Fluosol and its detergent 
oxatner 18% limit myocardial reperfttsion-induced 
iI\lgr$ bowever, tbe lntderlytng mechanism(s) atn unce 
Mdkuis. A &es of in vlvo and ex vtvo studies were pe 
in n 3@-mitt temporaty corona 
ton, rabblls received a 
er 188 (equkslent % 
1); or 3) 5% dextrose (control). In protocol A, animals were 
subjected to eltber normoxic or hyperoxic reperfuston; in proto- 
cols B und C, byperoxk rqerfusfon was studied. In protocol B, 
q yotxtrdhd blood flow was assessed. In protocol C, ~~rno~b~ 
nuclear leukocyte function and myocardial myeloperoxfdase were 
determined, 
Early reperfusion with thrombolytic agents or by means of 
percutaneous transluminal angioplasty is the current treatment 
of choice for patients with acute myocardial infarction. AI- 
though cardiac mortality has decreased with the advent of 
thrombotic therapy, the impact of reperfusion on ventricular 
function has been modest (1,2). Experimental evidence (3-5) 
su ts that restcration of blood flow to previously ischemic 
but reversibly injured myocytes may introduce ischemic ca- 
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R&k. fn rabbits subjected to normoxic reperfwsion, infn~t 
size (normalixed to risk region weight) was not significantly 
t among groups. In rabbit 
infnrcts were significantly 
and Fluosol treatment corn 
by treatment, nor was tbere suppression of polymorphonuelear 
leuhocyte function. 
Con&sions. Fluosot and peloxaruer 188 reduce infarct size in 
rfnsion. Suppression of poly- 
morpbonnckar feukocyte fnnction was not demonstrated, suggest- 
tng a greater role for increased arterial oxygen delivery in 
salvaging iscbemic myocardium. 
(J Am Coll Cadid 1994;24:1098-108) 
tabolites or cellular elements (neutrophils, platelets), or both, 
which could cause irreversible injury (the so-called “lethal 
reperfusion injury”). Therefore, recent efforts have focused on 
characterizing therapeutic agents that may be useful as adjunct 
therapy in limiting reperfusion-induced injury (6). 
One such agent, oxygenated perfluorochemical emulsion 
(Fluosol-DA 20%, Alpha Therapeutic Corp.), an acellular 
perfusate, has been shown (7-10) to reduce infarct size and 
improve contractile function in various experimental models of 
occlusion and reperfusion and in patients presenting with 
isolated acute anterior myocardial infarction. Pertluorochemi- 
cals are synthetic blood substitutes with a small particle size, 
low viscosity and high oxygen-carrying capacity (4,11,12). Fluo- 
sol consists of two perfiuorochemicals (perfluorodecalin and 
perfluorotripropylamine), a surfactant (poloxamer I@), glyc- 
erol, phospholipids and various electrolytes. Although the 
precise mechanism of myocardial infarct size reduction with 
Fhmsol is unknown, it is speculated (4) that its cardioprotec- 
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ting ~brin(Q~en)-induc 
anstrated that poloxamer 158 improves survival after experi- 
and increases blo 
loxamer 188 has 
arct size in the te 
ck, reduces tissue damage in frostbite 
w to ischemic areas of the brain. 
1 s~lowl~ (19,2O) to reduce: ~~~y~car~~~~~ 
coronary occlusion canine model. 
ret size reduction associated with 
Fluosol trea~l~ent may be limited to its ~l~~li~~ito~ actions on 
tbc ncutrophil and that littlc additional benctit may be derived 
from its oxygen-car~iilg properties. Suppression of ncutrophil 
function by Fluosol UlSioll has bcctl pril~~~ri~y iltt$3Wtd IO 
its detergent poloxa ’ 1SS (D-24). In light of thcss findings, 
we postulated that sol treatment, hrough suppression of
neutrophil function, would reduce ischemidreperfusion injuty 
in the absence of increased partial pressure of arterial oxygen. 
The aim of the present investigation was to assess 1) 
whether xic reperfusion contributes to the efficacy of the 
perfuor cal Fhtosol or its detergent component polox- 
amer IS8 for myocardiai infarct size reduction; and 2) whcthcr 
suppression of polymorphonuclear leukocyte function is an 
underlying determinant of cardioprotection with either of 
these agents. 
The present investigation conformed with the Guide for the 
Care and Use of Laboratory Animals published by the U.S. 
National Institutes of Health (NIH publication No 85-23. 
revised 19S5) and the Ldhoratory Care and Use Committee at 
the Armed Forces Institute of Pathology, Washington DC. 
Experimental prep~~~~ion. Male New Zealand White rab- 
bits (2 to 3 kg) w!cre quarantined for at least 1 week before 
study. Rabbits were anesthetized with intravenous sodium 
pentobarbital (20 to 25 mg/kg body weight), intubated and 
placed on a positive-pressure respirator (Harvard Apparatus). 
Additional sodium pentobarbital (6 mg/kg) was administered 
as required. Rabbits were placed on a warming blanket to 
maintain normothermia during procedures. An l&gauge cath- 
eter was positioned in the left carotid artery for blood pressure 
measurements and arterial blood gas analysis. Electrocardio- 
graphic (ECG) lead I1 and hemodynamic measurements were 
recorded on a multichannel Gould ES-1000 recorder. A left 
thoracotomy was performed at the fourth intercostal space 
under aseptic conditions. The pericardium was incised, and the 
large obtuse marginal branch of the left circumflex coronary 
artery was identified. A 4-O cardiovascular silk ligature was 
placed around the artery -0.5 to 1 cm from the atrioventric- 
ujar (AV) groove. The ends of the ligature were threaded 
l0OS g, forming a snare that 
wou coronary artcry. Before 
coronary ligation, animals recei an intravenous hohis of 
helparm sodium (250 U!kg). Coronary artery occhtsion was 
apparent by the development of regional epicardial cyanosis 
and ST segment elevation on the ECC. ~yocardia~ reperfu- 
sion was visually confirmed by the restoration of blood flow 
through the large obtuse marginal branch artery and the 
disappearance of epicar ial cyanosis. IIn protocol A, reperfu- 
sion was further confirmed histologically by the absence of 
po~ymorph~nl~c~ear letikocytes concentrated at the bsrde~ 
ns of infarcted and viable myocardium. 
t size. Before the start of t 
ized to one of the followi 
treat~i~c~its: 1) Fluosol (n = 19); 2) poloxamer 188 
8, ;I trademark of BASF Corp.) equivalent % w/v to 
19); or 3) dextrose (control group to account for 
bcmodihttion, n = IS). Fluosol consists of three separate 
that WC mixed togcthcr before administration: I) the Fluosol 
emulsion (pcr~uorodeca~~i~, pcr~uorotri-~?-propy~a~niae, polox- 
amer 188, glycerin, yolk phospholipid and potassium oleate); 
2) solulion 1 (soditim bicarbonate and potassium chloride); and 
3) solution 2 (sodium chloride, dextrose, magnesium chloride and 
calcium chloride). The additive solutions 1 and 2 serve to adjust 
the pH, ionic strength and osmotic pressure in the final 20% 
emulsion. The final composition of Fluosol when prepared for use 
was as follows (composition g/di): perfluorodecalin 14.0, pc&ro- 
rotri-jr-propylamine 6.0, poloxamer 188 2.72, glycerin OS, yolk 
phospholipids 0.4, potassium oleate 0.032, sodium bicarbonate 
0.21, potassium chloride 0.034, sodium chloride 0.60, dextrose 
0. IX, magnesium chloride hcxabydratc 0.043 and calcium chloride 
dihydratc 0,036. Bcforc USC, poloxamcr 18X was dissolved in 5% 
dcxtrosc in water and tiltcrcd through a 0.2~pm filter. Electrolytes 
(solutions I and 2) were similarly added to the poloxamcr 1X8 and 
5% dextrose (control) solutions before infusion as well. 
Coronary occlusion was maintained for 30 min (Fig. 1). At 
25 min into the occlusion ptriod, Fluosol, poloxamer 188 
((,75 mg/kg) or dcxtrosc was administered (25 ml/kg) over 
30 min through the marginal ear vein with an Infusion pump 
(Harvard Apparatus). At treatment, rabbits were randomized 
to room air v:ntilation (normoxia) or 100% oxygen (hyper- 
oxia). Oxygen therapy was maintained for 3 h of reperfusion. 
Arterial blood gases were monitored throughout the study. 
After 45 min of reperfusion, the thoracic cavity was closed, and 
the animals were allowed to recover. Rabbits receiving oxygen 
therapy were transferred to an isolation chamber continuously 
saturated with 100% oxygen. Levels of oxygen in the chamber 
were monitored with an oximeter probe. 
Cvite~ia for cdusion. Exclusion criteria for infarct size 
measurement were established before the start of the study: 
failure of the occluded vessel to rcperfuse, the area at risk 
~35% or >75% of the left ventricle (distal to the level of 
coronary occlusion) and failure of the rabbit o survive 48 h of 
rep&u&n. Hearts in which the risk region is <35% of the left 
ventricle develop disproportionately smaller infarcts or ab- 
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ventibtion_ Room Aii (ProWcol A) or 100% oxygen 
__-_------------- 
Figure 1. Summary of experimental 
protocol (see Methods). R, = treatment 
(dextrow Fhosol or poloxamer 188) 
infused over 30 min starting at 25 min 
after corJna6y artery occlusion. 
(e, 25 mkr 0, R-l $45 min) 
(R, 2s mln 0, R-l 5.45 mill) 
-pmtocd 6. (B, ZS rnln 0, R-30, 180 min) 
sence of infarction (25). Hearts in which the area at risk is 
375% of the left ventricle were excluded because of previous 
observations of large infarcts to be associated with clinically 
apparent heart failure. 
Eighty-three animals underwent coronary occlusion, of 
which eight had no rcperfusion (three in the poioxamer 188 
narmoxic rcperfusion group; four in the Fluosoi group: and 
one in the poloxamcr 188 hypcroxic rcperfusioa group). Scvcn 
rabbits did not survive the 48 h of reperfusion (two in the 
control group; two in the Fiuosoi normoxic repcrfusion group: 
three in the Fluosoi hyperoxic reperfusion group). Thercfcre. 
hearts from #I animals were prepared for histologic analysis. 
Attimul et~!rtlhunusiu. Forty-eight hours after myocardial in- 
farction, rabbits were reanesthetized, intubated and ventilated 
with room air. A left thoraco:omy was performed, and the left 
obtuse mtarginal coronary artery was ligated at the site of the 
previous occlusion. Monastryi blue dye (I 
Nem~~rs) was administered through the marginal ear vein for 
I min for delineation of the area at risk. Hearts were removed 
and arrested in diastole by immersion in isotonic potassium 
chloride and then ftxed in 10% phosphate-buffered formaiin 
for at least 48 h before histologic processing. 
H&&g& ana&.s. Each heart was sectioned (five slices, 
each 2 to 3 mm thick, parallel to the posterior AV groove to 
the level of coronary occlusion) and photographed for later 
quantitation of the area at risk. The right ventricle was 
removed, and the left ventricular slices were weighed and 
processed for light microscopy. Microscopic sections (4 pm) 
were prepared and stained with hematoxyiin-eosin and Mas- 
son’s trichrome stain. The area at risk was marked by super- 
imposing the paraffin blocks on the histologic sections; the 
location of the risk region was further confirmed from photo- 
graphs of the left ventricular slices. The area at risk and area of 
trecrosis (stained by tichrome stain) were enlarged (x10) 
using a microscopic projector. The percent of the area at risk 
and necrotic area were calculated by computerized pianimetry. 
The areas of the left ventricle risk region and infarct were 
traced, and the weights of these regions were derived from the 
total left ventricular mass. Analysis of infarct size was per- 
formed by an observer unaware of the treatment groups. 
ow. In a subse- 
ow in the various 
treatment groups was measured in animals subjected to isch- 
cmia foiiowcd by hypcroxic reperfusion (Fig. 1). Rabbits were 
instrumented as in protocol A except for the additional 
piacemcnt of a Icft atria1 catheter for microsphere injection 
and a left fcmorai artery catheter for microsphere blood 
sampling. Myocardiai blood flow was determined at baseline, 
after 25 min of occlusion and at 30 and 180 min of reperfusion, 
as described previously (26). At 3 h into reperfusion, the area 
of risk was determined as in prot I A, and animals were 
cuthanized with an overdose of sodium pentobarbitai. 
Analysis of regional myocatdiaf blood flow. After euthana- 
sia, tissue samples (IOU to 300 mg) were obtained from the 
middle left ventricular slices from the postischemic reperfused 
and nonischemic (control) regions, and each was divided into 
epicardial and endocardiai halves and weighed. Myocardiai 
and reference blood samples were counted in a multichannel 
well-type automated gamma counter (Minaxi-gamma, Auto- 
gamma SOUO Series, Packard Instrument Co.). Background 
contamination and overlapping radioactivity from multiple 
isotopes were corrected by using a matrix correction method 
(Compusphere Software, Packard Instruments Co.). Myocar- 
dial blood flow was calculated as described previously (26). 
Motphoiogic assessment of polymotphonuclear leukocytes. 
Myocyte and capiiialy injury was assessed in tissue from ischemic 
and nonischemic regions. Specimens were cut into l-mm” pieces, 
lixed in McDowell-Trump solution and stored at 4°C. Tissue was 
transferred to 1% osmium tetroxide in 0.1 moVliter of cacodyiate 
buffer, dehydrated and embedded in effapoxy. Smithin sections 
(0.5 to 2 m) were cut and stained with 1% to!lridine blue and 
examined by light microscopy. Areas with the most capillaries 
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were selected for ultrathin section cutting, stained with UP~IIYI 
acetate and lead citrate and ~xarnj~ed fin a Zeiss 909 IGF 
electron microscope. 
ocyte injury was assesse 
~do~rdi~rn and ~~~~a~d~~~~ ( 90 consec- 
each region; i.e., 20 capillaries per heart), 
sly (8). Each electron micrograph was 
assigned a myocyte and endothelial number score. The myo- 
cyte score was highest for irreversible injmy. The endotbelial 
score was weighted toward endothelia! obstruction by cellular 
elements (red blood cell, platelets, polymorphonuclear leuko- 
cytes), fibrin deposition or severe endothelial swelling and 
disruption of capillary integrity. Myocyte aild capi99ary injury 
scores were summed and divided by the total number of 
capillaries examined to dcrivc a final grade for each heart. 
were subjected to 30 min of 
coronary artcry occlusion and 3 h of hypcroxic rc9)crfusion and 
were trcatcd with Fluosol, pok~xamcr X or dextrose. as 
previously described in protocol B. Auil 
by exsanguination after insertion of a I/l-gauge cannula into 
the abdominal aorta. Blood was collected into hvo 60-m] 
syringes, each containing 5 mI of acid citrate dextrose solution. 
Po9ymorpl~o~uc9ear leukocytes were isolated by use of a mod- 
ified method of Sessa and Mullane (27). A polymorphonuclear 
leukocyte-rich plasma fraction was first obtained by dextrdn 
sedimentation in which 3 ml of 0% dextran (molecular weight 
500,000) solution was added per 10 ml of blood. The blood- 
dextran mixture was left for 2 h at room temperature. The 
leukocyte-rich fraction was layered onto a Ficoll-hypaquc 
density gradient (Histopaquc 9077, Sigma Corp.) and centri- 
fuged at 2oOg for 20 min. Residual crythrocytcs wcrc removed 
by hypotonic lysis with deionized distilled water. Examination 
of the cell suspension by fluorescent microscopy revealed 
>95% viability as assessed by propidium iodide. Experiments 
were completed within 4 h to ensure the use of healthy cells. 
Superoxide radical production. Before the assay, polymor- 
phonuciear leukocytes (2 X IO” cells/ml) were preincubated 
for 15 min at 37°C in complete Gey’s balanced salt solution 
(GBSS) containing cytochalasin B at 5 &ml. Superoxide 
anion production was assessed by the reduction of ferricyto- 
chrome c, 320 pg (type V-A from bovine heart, Sigma Chem- 
ical), using I x 90” cells in a final volume of 200 ~9 of GBSS 
with or without N-formylnorleucylleucylphenylalanine 
(FN-LLP, IO-’ to lo-” mol/liter). Reduced cytochrome c 
production was measured at 550-nm wavelength using a 
THERMOmax microplate reader (Molecular Devices Corp.) 
equipped with kinetics assay software (SOFTmax, Molecular 
Devices Corp.). Each assay had an interna control in which 
;uperoxide dismutase was added before incubation. The 
amount of superoxide anion production was calculated using 
the method of Pick and Mizel (28) and is expressed in 
nmo9/1 x lo5 pvlymorphonuclear leukocytes. 
Lysozyme release. Lysozyme release was analyzed by mea- 
suring absorbance changes of Micrococcus lysodeikticus bacte- 
ria suspension as prev tic mea- 
s~~erne~lts (using a mic made on 
polymorpho~~clea~ %e 90”) exposed to either 
SS containing 0.2% bovine serum albumin, 
/liter HEPES, artd cytochalasin 83 (lo-’ m&liter), or 
addition of FN-UP (10 -’ to IO-’ moi/liter). Each 
experiment had internal controls to determine total lysozyme 
content after treatment with T&on-X (0.05%) and sonication. 
The results are expressed as a percent of die total i~trace99~9ar 
9ysozyme content and are presented as the mean value c SE 
of triplicate assays. Fluosol 9las previously been shown not 
interfere with this procedure (6). 
Ci!crnotnxi.s. Chemotaxis was assayed in 
is chamber according to tile methods of 
cfly, po9yni~~rp~~onnc9ear leukocytes (1 
suspended in complete G SS containing 0.2% hovine serum 
albumin and 20 mmol,‘litcr EPES. Assays were per- 
formed in which the total num r of Cc99s migrating througlr 
polyvinylpyrrolidone-free polycarbonate membranes (S-pm 
ports) (Nudeoporc Corp.) wcrc quaatificd. C~~arn9~crs were 
incubated for 30 min at 37°C in bumid air. Chcmoattractants 
were diluted in complete GBSS containing 0.2% bovine serum 
albumin. After incubation, nonmigrating cells were wiped 08 
the filters, and the filters were fixed in methanol and stained 
with iff-Quick (Dade Diagnostics, IEIC., Aguada, uerto 
Rico). Migrated cells were counted with an Optomax System 
IV image Analyzer (Optomax, 9nc.). Random migration was 
asscsscd by quantifying cclt migration in response to medium 
alone. The data are prescntcd as mean value ?I SEM of 
triplicate assays and represent the total number of migrating 
polymorphonuclear leukocytes/mm’ of filter surface. 
lhcrmi~tation of nly~Jlop~r~.~iduse ctivi~ in myoctrrdial ri.s- 
sue. After exsanguination, hearts were rapidly excised and 
perfused retrogradely at 6” to X0 mm g through the aorta 
with lactated Ringer’s solution to clear the coronary circulation 
of blood. To define the area at risk, tile left obtuse marginal 
artery was reoccluded, and 10 ml of fluorescent zinc cadmium 
sulfide particles (Duke Scientific) suspended as 1 mg/ml in 
normal saline solution was infused into the aortic stump (32). 
Tissue samples were obtained for myeloperoxidase deter- 
ination from the middle left ventricular slices from the 
posterior and anterior walls (area at risk and nonrisk region, 
respectively) and weighed. Myeloperoxidase was determined 
using the method of Bradley et al. (33) as modified by Mullane 
et RI. (34) and Schierwagen et al. (35). Briefly, myocardial 
tissue (950 to 250 mg) was homogenized in 10 ml of 
0.02 mol/liter potassium b&r, pH 7.4. One milliliter of the 
homogenate was centrifuged at 10,OOOg for 5 min at 4°C. The 
supernatant was discarded, and the pellet was resuspended in 
I ml of 0.05 mol/liter potassium phosphate buffer (p 
containing 0.5% hexadecyltrimethyl ammonium bromide 
(Sigma Corp.). The suspension was frozen and thawed once, 
briefly sonicated (Branson Sonifier, mode9 250) on ice for 95 s 
and incubated at 60°C for 2 h. The suspension W~IS centrifuged 
again, and the supernatant was assayed for myeloperoxidase 
activity. Supernatant myeloperoxidase was measured spectra- 
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t 
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Reperfusion(min) 
photumetrically at $68 nm after reaction with o-dianisidinc 
(0.167 mg/ml) (Sigma Corp.) and hydrogen peroxide 
0). ) (Sigma Corp.), 
%t&stica. BaFa re presented asmean value & SIlM for all 
variables analyzed within each group. Serial mcastnements i  
ups (hemodynamic variables, regional myoeydrdial blood 
flow) were analvzed by repeated-measures anab+ of variance 
(ANOVA). Individual comparisons betwecu groups were per- 
formed by one-way ANOVA, and statistical differenc,?s were 
determined using the Scheffe multiple range test. Regression 
coefficients for the relation between area at risk weight and 
infarct weight were tested for equality as described previously 
(36) using Statistical Analysis Software (S_4S Institute); p = 
0.05 was considered significant. 
esults 
f%Wcol A: measurement of infarct size. Animal exch~sion. 
Of the 68 hearts evaluated for infarct size, there were 12 cases 
in which the area at risk was <35% or >75% of the left 
ventricle (1 in the control group; 4 in the Pluosol group; 2 in 
the poloxamer 188 normoxic reperfttsion group; and 2 in the 
control group; 2 in the Pluosol group; 1 in the poloxamer 188 
hyperoxic rep&&ion group, respectively). Thus, data from the 
Graphs of hemodynamic changes dur- 
rimental protocol A. In rabbits rcper- 
fused under narmoxic or hypcroxic conditions, no 
significant diffcrenccs were not in heart rate 
(NR), systolic blood pressure P) and ratc- 
pressure product (RPP) among groups. Symhots 
nnd bars rcprcscnt the mc:m vnluc z!z SEM for 
each experimental group. BPM = bcats/min. 
remaining 56 rabbits were included in the final analysis of 
infarct size (10 in the control group; 10 in the Fluosol group; 10 
in the poloxamer 188 normoxic reperfusion group; aud 8 in the 
control group; 9 in the FLosol group; 9 in the poloxamer 188 
hyperoxic reperfusion group, respectively). 
Hemdyumic vuriablcs. No significant differences among 
treatments were observed in heart rate, systolic blood pressure 
and rate-pressure product during the course of monitoring 
(Fig. 2). No hypotensive episodes were observed inthe rabbit 
as a result of Fluosol infusion, unlike the blood pressure 
reduction observed inthe canine infarction model (37). 
Blood gas anufysis. Blood pH and arterial carbon dioxide 
partial pressure values before ischemia nd at 45 min of 
reperfusion were comparable in all groups (Table 1). Arterial 
oxygen partial pressure (Paz) values were similar among 
rabbits ventilated with room air, and animals ventilated with 
100% oxygen showed the expected increases in arterial Pea at 
45 min of reperfusion. Arterial PO, measurement at 15 min of 
reperfusion was similar to that observed at 45 min (data not 
shown). 
Infarct size. Nomoxic reperfusion. Morphometric vari- 
ables of infarct size are shown in Table 2. The area at risk 
weight in poloxamer 188-treated rabbits was significantly 
smaller than that in control animals (1.38 2 0.10 gvs. 1.86 5 
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‘Fahrle B. Blood Gas Aflaiysis Before Ischesnia (B seline) and 45 min 
After Reperfusion ong Various Treatment Groups 
PXOz Pa02 
Treatment PB-8 (mm W (mm Hg) 
N0fSlIQXirn 
Control 
Baseline 7.41 rt 0.03 30.7 2 1.3 69.9 5 3.1 
45 min Rep 4.45 It 0.03 29.4 ? 1.4 64.5 2 2.6 
Poloxamer 158 
Baseline 7.49 t 0.02 25.3 2 1.2 84.5 Ic 3.9 
45 min Rep 7.52 ‘c 0.02 22.6 f 1.4 96.7 + 4.5 
FhJosol 
Baseline 7.4s r 0.01 28.4 2 1.1 86.1 t 5.6 
45 min Rep 7.50 + 0.02 26.4 rt 1.4 7X1 + 5.6 
Nyperoxia 
Control 
Baseline 7.39 L 0.03 31.2 2 2.0 71.6 ‘c 6.9 
4.F min Rep 7.41 + 0.02 31.9 L 2.5 4tw.6 ? 34.8 
POlWWlW 188 
Baseline 7.46 + 0.03 26.4 1: I .b W2.4 ?: 5.2 
4.5 mia Rep 7.55 t 0.02 29.4 c 1.2 432.6 2 54.5 
Fluosol 
Baseline 7.45 ! 0.02 28.4 -c I.6 71.5 24.3 
45 min Rep 7.52 2 0.02 26.0 !I 1.7 493.8 t 24.8 
Data presented are mean value 2 SEM. No significant differences in pH and 
partial pressures of arterial carbon dioxide (Pace*) and oxygen (Pao,) were 
noted among the groups. Rep = reperfusion. 
0.10 g, respectively, p = 0.002). However, there were no 
significant differences in infarct size in poloxamer ISS- and 
Fluosol-treat;d rabbits when infarct weight was expressed as a 
percent of risk region weight (43 f- 5% and 54 + 3%, vs. 
control 53 5 5%, respectively). 
Hyproxic repe@sion. No significant differences in risk 
regions were observed between groups (Table 2). Infarct size, 
when expressed as a percent of the area at risk weight, was 
s~g~i~ca~t~y smaller in both poloxamer 188- and Fluosol- 
treated rabhits then in control animals (40 + 3% and 36 c 3% 
loxamer 188 [p = 0.0 
Efect of the area at risk on infarct size. The effect of area at 
risk weight on the analysis of infarct size was determined 
because this variable was sigiii~ca~~~y smaller in the normoxic 
reperfused poioxamer 188 group. The associatiora of infarct 
weight and area at risk weight was ilot significantly different in 
normoxic reperfused poloxamer 188- (slope 0.49 2 0.08) (Fig. 
3A) arad Fluosol-treated (slope 0.53 -C 0.05) (Fig. 3B) rabbits 
from contr~ol animals (0.55 t- 0.04). In rabbits ubjected to 
eroxic reperfusion, the lower slopes for poloxzmer 188 
lg. 3C) (slope 0.47 -t 0.05, p = 0.05) and Fluosol (Fig. 3D) 
(slope 0.35 Z?Z 0.04, p = 0.0004) -treated rabbits compared with 
control animals (0.55 t 0.04) confirm the ccrdioprotcctive 
effects of these agents. 
uw. AlziVlal f?K11- 
~~~j~~ and e&csiQIl. Thirty animals were subjected to coronary 
artery occlusion. Of these seven were excluded because the 
area at risk was ~35% or >75% of the left ventricle (four in 
the control group, two in the poloxamer 188 group, one in the 
Fluosol group), and one was excluded in the Fluosol group 
because of technical reasons. Therefore, 22 animals were used 
for statistical comparisons (6 in the control group, 8 in the 
poloxamer 188 group, 8 in the Fluosol group). 
Blood ~?Qw. No significant differences were noted in 
blood gases or hemodynamic variables among treatments 
during the protocol. Regional myocardial blood flow at 
baseline in the endocardial and epicardial areas within the 
area at risk was similar in all treatment groups (Fig. 4). At 
30 min of occlusion, flow in the ischemic region was 
markedly reduced, whereas at 30 min of reperfusion, all 
Table 2. Comparison f Myocardial Infarct Size Among Treatment Groups Subjected to Either 
Normoxic or Nyperoxic Reperfusion 
LV AAR AN AN/AA R
Treatment wt (8) wt (6) wt (g) (B) 
Normoxia 
Control 3.15 2 O.I4 1.86 c c.10 l.oo? 0.12 52.6 It 4.h 
(n = 10) 
Poloxamcr 188 2.95 2 0. IO 1.38 c 0.10* 0.62 2 O.iL 42.9 + 4.1 
(n = 10) 
Fluosol 3.29 2 0.16 1.77 +- 0.12 0.98 ? 0.1 I 53.9 + 3.4 
(n = 10) 
Hyperoxia 
Control 2.99 f 0.1 I 1.6: j: 0.14 0.89 2 0.07 54.1 ir 2.7 
(n = 8) 
Poloxamer 188 2.80 1: 0.07 1.36 1 0.09 0.59 !I 0.07t 39.1 c 3.25 
(n = 9) 
Fluosol 2.86 2: 0.12 I.61 IO.09 0.59 ? 0.05.t. 36.4 2 3.011 
(n = 9) 
*p = 0.002, poloxamer 188 versus control. tp = 0.015 and #p = 0,012, poloxamer 188 and Fluorol versus control, 
respectively. §p = 0.008 and [Ip = 0.001, poloxamer 186 and Fluosol versus control, respertiveiy. Tlte area at risk @AR) 
was determined as percent of the left ventricle (LV) distal to the level of coronary occlusion. Data present*:d are mean 
value -C SEM. AN = area of necrosis. 
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Rma-at-Risk WeQht (9) 
trcatmcnt groups displayed marked hypcrcmia. A significant 
dcctcasc in blood flow occurred in the ischcmic cndocar- 
dium and @cur&urn nt 180 min of rcpcrfusion in alI groups. 
Howcvcr, Fluosol- and poloxamcr I%-trcatcd rabbits 
showed greater preservation of How in the ischcmic cndu- 
cardium at 180 min of repcrfusion than did control animals 
(1.83 %. Cl.82 and 1.23 2 0.16 mllmin per g vs. 0.X!? -C 
0.12 mlimin per g, p = 0.001 and p = 0.08, rcsp?ctively). 
&XVKHI micnAscopy. Myocyte and cndothclial injury was 
assessed within the central ischemic arca of each heart. The 
mean myocardial and cndothclial injury scores were similar in 
all groups (Table 3). The nonrisk region showed minimal 
mqhologic changes consisting of mostly mild endothelial cell 
swelling and cytoplasmic blebs, with the surrounding myocar- 
dium showing mild mitochondrial swelling and clearing of 
matrix and no evidcncc of flocculent densities. 
Rdoegl C. Aninwl nmiality mnd mltrsiorr. Twenty-six 
rabbits undcrwcnt coronary artcry occlusion. 0f these, two 
died of rcpcrfusion arrhythmias (control Group); two had risk 
regions S35Q or >7S% of the left ventricle (one in the 
poloxamer 1~88 group, one in the Fluosol group: two had no 
reperfusion (one in the poloxamer 188 group, one in the 
Fluosol group), and two were excluded for technical reasons 
(one in the control group, one in the Fluosol group). There- 
fore, 18 rabbits (6 in each group) were used for statistical 
comparisons. 
Figure 3. Plot of infarct weight its B 
function of the nrt‘u at risk wcighk 
Last-squares regression lines through 
the origin arc shown. No diffcrcncc in 
the slope of thu relation Mwccn in- 
filrCt illld i~rCi1 ilt risk weight \WS lh 
stmcd for tither p&sis;lmcr I# (A) or 
~~~t~i~f~flil~~~ic urriuhls md circddrg polyrnor~)~lorucleav 
lertkocyk~:v. No significant dificrcnccs wcrc noted in blood 
gases or hcmodynamic variables among treatments during the 
protocol. The number of circulating polymorphonuclcar lcu- 
kocycs before coronary artcry occlusion were similar among 
treatment groups (Table 4). Coronary artery occlusion/ 
rcpcrfusion resulted in an approximate threefold to fourfold 
incrcasc in the number of circulating polymorphonuclear 
leukocytes, and statistical differences were not observed among 
trcatmcnts. 
Myocardicrl tn@qmxidasc. Polymorphonuclcar Icukocyte- 
specific myeloperoxidasc activity in the nonischemic myocardium 
(arca not at risk) was minimal, indicating that few cells infiltrated 
the nonischemic myocardium, and no significant differences oc- 
curred between treatments (Table 3). Myeloperoxidase activity 
within the ischemic myocardium (area at risk) was increased 
(threefold to fivefold) relative to the nonischemic region, demon- 
strating enhanced polymorphonuclear leukocyte infiltration asso- 
ciatcd with ischemia/rcperfusion. No significant difference in 
myeloperoxidase activity in the ischemic myocardium was ob- 
served among treatment groups at 3 h of reflow. 
Ex vivo polymorphonuclear leukocytes experiments. Srr- 
permide anion production. Minimal superoxide radical pro- 
duction was detected in nonstimulated polymorphonuclear 
leukocytes preincubated with cytochalasin B over the lo- 
min assay period (Table 5). Addition of FN-LLP elicited a 
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igwe 1. Serial changes in re- 
gional myocardial blood flow 
(RMBF) in epicardial (A) and 
endocardial ischemic zones in 
the various tment groups. No 
significant differences were noted 
iUllO!lg groups at bilSClillC occlusion 
aud 30 min of reperfusion. At 
IX0 min of repcrfusion, Fluosol- 
and p~~O~~~~~-tr~i~t~~ ilkll;llS 
SllOWd a grcmr pWXlWltiOll of 
blood flow in thr endocardial rc- 
gions, whereas in the epicardial rc- 
line 180. 
concentration-dependent increase in superoxide anion gener- 
ation significantly greater in poloxamer 1Wtreated animals 
than in control animals (IO- ’ mmolfliter FN-LLP; p = 0.038). 
Superoxide anion production in stimulated and nonstimulated 
cells from Fluosol-treated and control rabbits was similar. 
Proreolytic etzzyttw tdcwsc~. Addition of FN-LLP (10~ ’ to 
10 ” mmol/liter) elicited a concentration-dependent increase 
in lysozyme release from polymorphonuclear leukocytes prc- 
incubated with cytochalasin 93 compared with nonstimulated 
cells (Table 5). No ! ignificant differences in lysozyme release 
were noted among treatment groups. 
Clretnotuxis. Addition of FN-LLP (IO-’ and lo-” mmol/ 
liter) elicited a concentration-dependent increase in polymor- 
phonuclear leukocyte chemotaxis relative to nonstimulated 
cc99s (Table 5). No differences in polymorphonuclear leukocyte 
migration were noted among treatment groups. 
t stud!. The separate effects of Fluosol and its 
component poloxamer 188 in a rabbit mode9 of 
ischemialreperfusion-induced myocardial injury were investi- 
gated. Significant infarct size reduction was observed with 
administration f intravenous F9uoso9 orpoloxamer 188 during 
the perireperfusion period. owever, the efficacy of these 
agents was dependent on increased arterial PO,; in normoxic 
reperfused hearts, infarcts were not sigmficantly different from 
those in control hearts. In another part of the study, endocar- 
dial blood flow at 3 h of reperfusion in the ischemic zone in 
hyperoxic reperfused rabbits was better preserved with F9uosol 
and poloxamer 138 treatment. Histologic examination of the 
ischemic region showed no significant differences in capillary 
injury among treatment groups. In subsequent studies, myelo- 
Table 3. Histopathologic Evaluation of Capillary and Myocyte Injury and Biochemical Determination of Cardiac Myeloperoxidase in the 
Three Experimental Groups of Rabbits Subjected to 30 min of Coronary Artery Occlusion and 3 h of Reperfusion 
Cardiac Myeloperoxidase Activity 
Capillary Injury Myocyte Injury (WOO mg tissue) 
Nonischemic Ischemic Nonischemic lschemic Nonischemic lschemic 
Control 0.41 2 0.12 1.92 -c 0.5X 0.54 ? '3.12 3.02 2 0.18 0.07 c 0.01 0.27 z!z 0.06 
Poloxamer 188 0.46 2 O.hQ 1.78 -c &IO 0.51 ?r 0.08 2.79 -c 0.40 0.10 -c 0.04 0.30 t 0.06 
Fluosol 0.37 ?I 0.43 1.72 2 0.73 0.36 + 0.11 3.40 rt Cl.23 0.08 z! 0.03 0.27 " 0.06 
No significant differences were noted in capillary and myocyte injury scores or cardiac myeloperoxidase among treatment groups. Capillary and myocyte injury 
(protocol 6) was quantitated after electron microscopy of tissue samples derived from the central area of ischemia and nonrisk region (nonischemic) using morphologic 
criteria as outlined in Methods; five rabbits comprised each group. Cardiac myeloperoxidase (protocol C) was determined in six rabbits from each group. Data presented 
are mean value t SEM. 
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Tabled NomberofPMNs (mean 2 SEM) Before andAfter 
Coronary Artery Occlusion (lO“/liter, n = 6) 
Prewclusion Poslreperfusion 
Cotltrol 1.4 “ 0.1 3.6 C 0.4 
Polowner 188 1.0 2 0.1 3.1 r 0.3 
Fluowl 1.5 2 0.1 3.1 z!z 0.2 
-~ ~ 
PMNs = pulymorphonuclear leukocytes. 
peroxidase activity was not affected by treatment, nor was there 
suppression of polymarphonuclear leukocyte function. ‘These 
results failed to provide evidence that suppression of polymor- 
phonuclcar leukocyte activation was the mechanism of myo- 
cardial salvage with either Fluosol or poloxamer 188. The data 
st that administration of Fluasol and poloxamer 188 
VES myocardial blood flow during hypcroxic reperfusion, 
presumably facilitating the delivery and extraction of oxygen to 
the. microvasculature and myocardium and resulting in dc- 
creased infarct size. 
R tdon Sl\lury and pe uotwchemicals. Because hy- 
peroxia can exacerbate free radical production (38), it has been 
speculated that hyperoxic reperfusion may increase myocardial 
injury. In the present study, infarct size in control animals was 
not affected by hyperoxic reperfusion. These data arc consis- 
tent with those of a recent study by Shnier et al. (39) in which 
3 h of hyperoxemic reperfusion failed to increase infarct size in 
rabbits subjected to 45 min of coronary occlusion. Thus, 
supplemental oxygen administered during reperfusion does 
not negate any of the cardioprotective effects of adjunctivc 
therapy such as pcrfluorochemicals, which require hypcroxia to 
be effective. 
The failure of Fluosol to reduce infarct size under normoxic 
conditions argues against the hypothesis that suppression of 
neutrophil function is the predominant mechanism of myocar- 
dial salvage with this agent (40). The present study suggests 
that the beneficial effects of Fluosol during reperfusion, at least 
in the rabbit, are primarily mediated by improvement of 
oxygen delivery through maintenance of coronary blood flow 
within the postischemic myocardium. In support of this mech- 
-anism, Kingma et al. (41) have demonstrated in canine myo- 
cardium that oxygenated Fluosol improves both coronary 
blood flow and oxygen transport in the endocardial region 
(compared with nonoxygenated Fluosol) even when coronary 
perfusion pressure is significantly reduced. Unlike hemoglobin, 
where oxygen is more tightly bound, Fluosol carries oxygen by 
direct solubility, and at high arterial PO, tissues will extract up 
?o 80% of the oxygen dissolved in Fluosol (42). This property 
was demonstrated in studies i 
Rude et al. (44) in which Flue 
availability and extraction compared with whole blood or 
he dextran or saline. 
Thcrc are few studies of tbc etTects of 
poloxamer I&q on’myocardial iscbemic injury (19,21).45). Re- 
covery from global ischemia in the isolated perfused rat heart 
was enhanced by treatment with poloxamcr 188 (45). Justicz ct 
al. (19) reported a 50% reduction in infarct size when poloa 
amer 188 (48 mglkg) was administered during the perireper- 
fusion period in an open chest canine model after 90 min of 
ischcmia and 24 h of reperfusion. In a closed chest canine 
model of 90 min of coronary occlusion and 72 h of reperf~si~~, 
Schaer et al. (20) reported that 48 h of continuous intrabfenous 
infusion of poloxamer I88 (75 mg/kg holus, followed by 
150 mgkg per h) under normoxic conditions improved left 
ventricular function and reduced infarct size by 44% without 
altering c~~~l~~teral blood flow. 
The bioavailability of poloxamer 188 is prolonged when it is 
a component of the Fluosol emulsion (Alpha Therapeutics, 
unpuhlishcd observation), and therefore, the benefits of polox- 
amer I88 may be increased when it is administered as part of 
Fluosol. In the present study,enhanced preservation of postisch- 
cmic myocardial blood flow was observed with Fluosol com- 
pared with poloxamer I88 alone. The quantity of bound versus 
Table 5. Summary of Ex Vivo Polymorphonuclear Leukocyte Experiments (mean -C SEM) 
Unstimuluted 
log [FN - LLP] (molfliter) 
Neutrophils -9 -8 -7 
PMN Release of Superoxide Anion (redwtbn of ferricytachrome c, nmul/lO 5 PMNs. n = 6) 
Cbntriti 0.31 + a.07 0.5 I 5 (1.09 I.67 + 0.30 2.50 2 0.28 
Polaxrmer 1% 0.24 + 0.40 I.18 + 0.31 3.46 + 0.60 4.31 + 0.55’ 
Flu& 0.30 ?J 0.07 OS’ . . I _ 0.17 * I .6S t 11.5 1 2.38 c 0.43 
Percwnl of Lywzyme Release hy PMNs (‘f total lyswymc rcleasc, n = 6) 
Control II 23 I8 -c 3 60 2 7 75 k 7 
I%Ihxwwr I%!+ II ‘3 2529 66%5 772 5 
RU0SQl 522 1522 55 2 7 73 2: 8 
Number of Migrated PMNs (n = 3) 
control 419 114 r - - Pokxamer 1,069 ?I 71 188 394 r 
191 - Fluasol LOSO 2 416 511 2 
230 - 1,354 + 411 
‘p = 0.038 cmwol versus poloxamer 188. FN-LLP = N-fo~ylnorleucylleucylphenylalanine; PMNs = polymorphonuclear leukocytes. 
-6 
2.93 -r 0.4.5 
4.35 -c 055 
2.45 4 0.43 
82 2 7 
72 t 6 
69 2 6 
f 249 1,561 
1,384 z 516 
1.653 f 448 
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I88 are unknown. T 
response. 
As for Fluosol, the mechanism(s) of infarct size reduction 
with poloxamer 188 is speculatjv oloxamer 188 reduces 
whole blood viscosity in blood con ng high concentrations 
of soluble ~bri~(~~eli) co 
ated in the presence of poloxamer 188, and this 
been shown to augment recombinant tissue plasl 
vator- and streptokinase-mediated fibrinolysis in an in vitro 
model of thrombosis (46). Colbassani et 81. (IN) suggest that 
poloxamer 188 umeliorates the adhesion alad friction produced 
by hydrophobic domains within injured cells and macromole- 
cules such as fibri resulting in improved blood Ilow in the 
microvasculature. e postulate that enhanced fibrinolysis in 
postischemic, repe sed areas may lead to increased myocar- 
dial blood flow. This effect, in combination with elevated 
arterial PO,, results in improved oxygen delivery and infarct 
size reduction. However, it is also plausible that decreased 
myocardial injury may lead to improvement in myocardial 
blood fow as observed with poloxamer 188 trcatmcnt. Fur- 
thermore, the efficacy of poloxamer 188 may be dependent on 
the presence of a well developed collateral circulation such as 
the canine model; collateral blood flow in the rabbit heart is 
essentially absent (47). 
Role of polym~~~~o~~c~e~r ~e~~~cyte f~~cti~~ i erfw 
sion injury. Neutrophils have been implicated in the cascade 
of events leading to lethal rcperfusion injury. Suppression of 
polymorphonuclear leukocyte infiltration in the previously 
ischemic myocardium has been demonstrated with Fluosol 
treatment (7,8). In these studies, polymorphonuclear leuko- 
cytes were measured following labeling with indium-I 11 (7) or 
by semiquantitative histologic techniques (8). The former 
methodology involves ex vivo manipulation of cells and results 
in variable labeling efficiencies (50% to 80%), which may 
contribute to the conflicting results with the present study; 
direct measurement of myocardial myeloperoxidase was used 
(after washout of circulating leukocytes) to quantify polymor- 
phonuclear leukocyte infiltration. 
In the present study, polymorphonuclear leukocyte function 
(as studied ex vivo) in Fluosol- and poloxamer 188-treated 
rabbits was similar to that in control animals. Siinilarly, an 
earlier study by Lane and Lamkin (21) failed to demonstrate 
Fluosol-mediated attenuation of superoxide anion generation 
and degranulation. It had previously been shown (48) that 
suppression of superoxide anion production in human neutro- 
phils exposed to Fluosol resulted from its ability to bind and 
sequester the activating agent phorbol myristate acetate, 
thereby preventing neutrophil stimulation (unpublished re- 
sults). We speculate that similar problems may be encountered 
sonized zymozan is used to activate ~e~tropll~~s in that 
entS ~ipopolysaccharide stimulation of cultured 
erefore, in the current study we chose FN-LEP as 
y~~~rpl~on~clear leukocyte stimulus, which may explain 
iscrepancy with Bajaj et al. (7), who used either phorbol 
or opsonized zymozan for ncutrophil activation. 
The lack of suppression of polymorphonuclear leukocyte 
chemotaxis in the present investigation with either Fluos~l or 
poloxamer 188 treatment may have occurred because the cells 
were washed during the isolation procedure, and migration 
assays were performed in serum-free conditions. Lane and 
Lamkin (21) found that washed polymorphonuclear leukocytes 
from rabbits treated with Fluosol (16 ml/kg) or an equivalent 
concentration of poloxamer 188 migrate similarly to control 
CCh in the presence of autologous plasma obtained before the 
infusion. However, polymorphonuclear leukocytes obtained 
before or after infusion, when combined with postinfusion 
plasma, show attenuated migratory responses (al). Although 
in the present study, the effect of postinfusion plasma on 
polyworplnonllclear leukocyte chemotaxis was not tested, de- 
termination of leukocyte infiltration in the iscbemic myocar- 
dium failed to show any differences between groups. 
S ~irn~t~t~~~§, Although animals were randomized to 
treat groups before coronary artery occlusion, the area at 
risk in rabbits treated with poloxamer 188 and reperfused with 
normoxic blood was by chance 25% smaller than those in the 
Fluosol and control groups. This difference may represent vari- 
ability in arterial branching, coronary artery size or the level of 
coronary ligation. Despite this inequality, valid comparisons be- 
tween groups were accomplished by normalizing infarct size as a 
percent of the corresponding risk region. Since infarct weight is 
directly correlated to risk region weight (50), dilferences in infarct 
size were further confirmed by analysis of variance. 
Cunclosions. In an animal model of low collateral blood 
flow, such as the rabbit, hyperoxic repcrfusion was required to 
demonstrate infarct size reduction with Fluosol or its detergent 
component poloxamer 188. Although previous studies in the 
canine model of temporary coronary artery occlusion have 
suggested that the mechanism of limiting infarct size with these 
agents was, at least in part, associated with suppression of 
neutrophil function, the present study failed to corroborate 
these results. Whether infarct size reduction with Fluosol is 
dependent on poloxamer 188 remains to be established. We 
conclude that Fluosol and poloxamer improve myocardial 
blood Row in areas of low-flow ischemia, thereby facilitating 
oxygen delivery to reversibly injured myocytes and resulting in 
decreased infarct size. 
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